Danyelza (naxitamab-gqgk) 40mg

Danyelza (naxitamab-gqgk) 40mg

$1,000.00

Danyelza is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response

Category: Tag:

Description

Danyelza (naxitamab-gqgk) is a monoclonal antibody used to treat high-risk neuroblastoma, a type of cancer that forms in nerve tissue, primarily affecting children. It works by targeting the GD2 antigen found on neuroblastoma cells, helping the immune system recognize and destroy these cancer cells. Danyelza is usually given in combination with GM-CSF (granulocyte-macrophage colony-stimulating factor) to enhance its effectiveness.

Reviews

There are no reviews yet.

Be the first to review “Danyelza (naxitamab-gqgk) 40mg”

Your email address will not be published. Required fields are marked *

Related products